Foghorn Therapeutics (FHTX) Net Cash Flow (2019 - 2026)

Foghorn Therapeutics' Net Cash Flow history runs 8 years deep, the most recent figure standing at $6.8 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 21.81% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $28.2 million (up 254.6% YoY), while the FY2025 annual figure was $27.0 million, up 208.37% from the prior year.
• Net Cash Flow for Q1 2026 stood at $6.8 million, up from -$8.5 million in the prior quarter.
• The five-year high for Net Cash Flow was $112.5 million in Q1 2022, with the low at -$152.4 million in Q2 2022.
• The 5-year median for Net Cash Flow is $6.8 million (2026), against an average of -$703294.1.
• Peak annual rise in Net Cash Flow reached 745.28% in 2024, while the deepest fall reached 744.84% in 2024.
• Foghorn Therapeutics' Net Cash Flow stood at -$35.4 million in 2022, then surged by 128.32% to $10.0 million in 2023, then tumbled by 122.17% to -$2.2 million in 2024, then tumbled by 280.31% to -$8.5 million in 2025, then jumped by 180.24% to $6.8 million in 2026.
• Business Quant data shows FHTX's Net Cash Flow at $6.8 million in Q1 2026, -$8.5 million in Q4 2025, and $16.8 million in Q3 2025.